Form 4: Puma Biotechnology CEO Alan Auerbach Sells Shares Under 10b5-1 Plan

Alan Auerbach, CEO of Puma Biotechnology, sold 18,885 shares of common stock on July 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Alan H. Auerbach, the President and CEO of Puma Biotechnology, sold 18,885 shares of the company's common stock on July 2, 2024.
• The sales were executed under a pre-arranged 10b5-1 trading plan adopted on December 17, 2020.
• The shares were sold at a weighted average price of $3.2685, with individual transaction prices ranging from $3.2601 to $3.3101.
• Following the transaction, Auerbach still beneficially owns 7,085,435 shares of Puma Biotechnology.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the specified range upon request.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a pre-arranged 10b5-1 trading plan suggests that it was planned well in advance and not based on any recent material non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates